Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma.


Journal

Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886

Informations de publication

Date de publication:
06 2021
Historique:
received: 22 03 2020
revised: 18 12 2020
accepted: 24 12 2020
pubmed: 24 1 2021
medline: 29 1 2022
entrez: 23 1 2021
Statut: ppublish

Résumé

Little is known about the metabolic regulation of cancer stem cells (CSCs) in cholangiocarcinoma (CCA). We analyzed whether mitochondrial-dependent metabolism and related signaling pathways contribute to stemness in CCA. The stem-like subset was enriched by sphere culture (SPH) in human intrahepatic CCA cells (HUCCT1 and CCLP1) and compared to cells cultured in monolayer. Extracellular flux analysis was examined by Seahorse technology and high-resolution respirometry. In patients with CCA, expression of factors related to mitochondrial metabolism was analyzed for possible correlation with clinical parameters. Metabolic analyses revealed a more efficient respiratory phenotype in CCA-SPH than in monolayers, due to mitochondrial oxidative phosphorylation. CCA-SPH showed high mitochondrial membrane potential and elevated mitochondrial mass, and over-expressed peroxisome proliferator-activated receptor gamma coactivator (PGC)-1α, a master regulator of mitochondrial biogenesis. Targeting mitochondrial complex I in CCA-SPH using metformin, or PGC-1α silencing or pharmacologic inhibition (SR-18292), impaired spherogenicity and expression of markers related to the CSC phenotype, pluripotency, and epithelial-mesenchymal transition. In mice with tumor xenografts generated by injection of CCA-SPH, administration of metformin or SR-18292 significantly reduced tumor growth and determined a phenotype more similar to tumors originated from cells grown in monolayer. In patients with CCA, expression of PGC-1α correlated with expression of mitochondrial complex II and of stem-like genes. Patients with higher PGC-1α expression by immunostaining had lower overall and progression-free survival, increased angioinvasion and faster recurrence. In GSEA analysis, patients with CCA and high levels of mitochondrial complex II had shorter overall survival and time to recurrence. The CCA stem-subset has a more efficient respiratory phenotype and depends on mitochondrial oxidative metabolism and PGC-1α to maintain CSC features. The growth of many cancers is sustained by a specific type of cells with more embryonic characteristics, termed 'cancer stem cells'. These cells have been described in cholangiocarcinoma, a type of liver cancer with poor prognosis and limited therapeutic approaches. We demonstrate that cancer stem cells in cholangiocarcinoma have different metabolic features, and use mitochondria, an organelle located within the cells, as the major source of energy. We also identify PGC-1α, a molecule which regulates the biology of mitochondria, as a possible new target to be explored for developing new treatments for cholangiocarcinoma.

Sections du résumé

BACKGROUND & AIMS
Little is known about the metabolic regulation of cancer stem cells (CSCs) in cholangiocarcinoma (CCA). We analyzed whether mitochondrial-dependent metabolism and related signaling pathways contribute to stemness in CCA.
METHODS
The stem-like subset was enriched by sphere culture (SPH) in human intrahepatic CCA cells (HUCCT1 and CCLP1) and compared to cells cultured in monolayer. Extracellular flux analysis was examined by Seahorse technology and high-resolution respirometry. In patients with CCA, expression of factors related to mitochondrial metabolism was analyzed for possible correlation with clinical parameters.
RESULTS
Metabolic analyses revealed a more efficient respiratory phenotype in CCA-SPH than in monolayers, due to mitochondrial oxidative phosphorylation. CCA-SPH showed high mitochondrial membrane potential and elevated mitochondrial mass, and over-expressed peroxisome proliferator-activated receptor gamma coactivator (PGC)-1α, a master regulator of mitochondrial biogenesis. Targeting mitochondrial complex I in CCA-SPH using metformin, or PGC-1α silencing or pharmacologic inhibition (SR-18292), impaired spherogenicity and expression of markers related to the CSC phenotype, pluripotency, and epithelial-mesenchymal transition. In mice with tumor xenografts generated by injection of CCA-SPH, administration of metformin or SR-18292 significantly reduced tumor growth and determined a phenotype more similar to tumors originated from cells grown in monolayer. In patients with CCA, expression of PGC-1α correlated with expression of mitochondrial complex II and of stem-like genes. Patients with higher PGC-1α expression by immunostaining had lower overall and progression-free survival, increased angioinvasion and faster recurrence. In GSEA analysis, patients with CCA and high levels of mitochondrial complex II had shorter overall survival and time to recurrence.
CONCLUSIONS
The CCA stem-subset has a more efficient respiratory phenotype and depends on mitochondrial oxidative metabolism and PGC-1α to maintain CSC features.
LAY SUMMARY
The growth of many cancers is sustained by a specific type of cells with more embryonic characteristics, termed 'cancer stem cells'. These cells have been described in cholangiocarcinoma, a type of liver cancer with poor prognosis and limited therapeutic approaches. We demonstrate that cancer stem cells in cholangiocarcinoma have different metabolic features, and use mitochondria, an organelle located within the cells, as the major source of energy. We also identify PGC-1α, a molecule which regulates the biology of mitochondria, as a possible new target to be explored for developing new treatments for cholangiocarcinoma.

Identifiants

pubmed: 33484774
pii: S0168-8278(21)00024-6
doi: 10.1016/j.jhep.2020.12.031
pii:
doi:

Substances chimiques

Indoles 0
PPARGC1A protein, human 0
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha 0
Propanols 0
SR18292 0
Metformin 9100L32L2N
Electron Transport Complex II EC 1.3.5.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1373-1385

Informations de copyright

Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest The authors have no conflicts of interest to disclose. Please refer to the accompanying ICMJE disclosure forms for further details.

Auteurs

Chiara Raggi (C)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. Electronic address: chiara.raggi@unifi.it.

Maria Letizia Taddei (ML)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Elena Sacco (E)

SYSBIO, Centre of Systems Biology, Milan, Italy; Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy.

Nadia Navari (N)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Margherita Correnti (M)

Center for Autoimmune Liver Diseases, Humanitas Clinical and Research Center, Rozzano, Italy.

Benedetta Piombanti (B)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Mirella Pastore (M)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Claudia Campani (C)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Erica Pranzini (E)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Jessica Iorio (J)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Giulia Lori (G)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Tiziano Lottini (T)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Clelia Peano (C)

Genomic Unit, IRCCS, Humanitas Clinical and Research Center, Rozzano, Italy; Institute of Genetic and Biomedical Research, UoS Milan, National Research Council, Rozzano, Italy.

Javier Cibella (J)

Genomic Unit, IRCCS, Humanitas Clinical and Research Center, Rozzano, Italy.

Monika Lewinska (M)

Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.

Jesper B Andersen (JB)

Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.

Luca di Tommaso (L)

Department of Pathology, Humanitas Clinical and Research Center, Rozzano, Italy; Department of Biomedical Sciences, Humanitas University, Rozzano, Italy.

Luca Viganò (L)

Department of Biomedical Sciences, Humanitas University, Rozzano, Italy; Department of Hepatobiliary Surgery, Humanitas Clinical and Research Center, Rozzano, Italy.

Giovanni Di Maira (G)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Stefania Madiai (S)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Matteo Ramazzotti (M)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.

Ivan Orlandi (I)

SYSBIO, Centre of Systems Biology, Milan, Italy; Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy.

Annarosa Arcangeli (A)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Paola Chiarugi (P)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy; Excellence Center for Research, Transfer and High Education DenoTHE, Florence, Italy.

Fabio Marra (F)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; Excellence Center for Research, Transfer and High Education DenoTHE, Florence, Italy. Electronic address: fabio.marra@unifi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH